I strongly believe you will lose your job and end up on the street if you continue to hold your short position; it is only a matter of time.
250 mil people around the world have diabetes, number will grow much bigger with obesity running rampid. Every insulin dependent diabetes will want to take a simple puff for their post meal glucose control. Tell me which diabetic isn't concerned that their bloood sugar shoots up to 300-500 after every meal. These people eat often, 3-8 small meals per day because they worry about large meals giving them too high of blood sugar level. You calculate that and you get back to me.
so you are saying, if management lies the stock goes up and if they tell the truth the stock still goes up. Where is the stock price going from here?
news flash, every transaction has an identifier to the hedge fund covering their shorts. Traders look for these identifier. They simply can't cover, retailers and day traders will rally every time they try to cover. They are trapped!
they are trapped like dirty rats! They are not allowed to cover until this becomes a massive squeeze to the 20's. Anytime they cover, a massive rally generates, they can't cover. Once the concrete news is out then they have no choice but to cover despite covering in the 20's and 30's. That's the real deal!
Look at netflix and tesla, these are the examples of heavy shorts going wrong. All these hedge funds will lose big time; they may go bankrupt after their coverages.
i will come back and repost when this hits $20/shre to remind you all of this party
Insurance companies have already approved Sovaldi for the treatment of Hep C, eventhough Sovaldi costs as much as $1,000 per pill. But Sovaldi guarantees a cure after a year which will cost most insurance companies as much as $200k per patient. However, over the long run someone who has Hep C will need hospitalization which could be very expensive, for the life of the patients.
The same applies to diabetes; patients who have diabetes will have diabetes for life, each hospitalization for diabetic ketoacidosis or hyperglycemia runs in the $10-20k. Loss of limbs, kidneys, eyesight, and heart are priceless and extremely costly to manage. Hence, insurance companies would want to approve Afrezza for better glucose control to keep patients out of the hospitals.
Again Afrezza's uniqueness is in it's ultra rapid action: quickest onset and peak effect in the market which allows fastest control of high blood sugar. Other forms of insulin, patients would have to wait 45-60 minutes for the insulin to kick in. With current treatments, hospitalization of diabetes related complications probably accounts for 30% of the healthcare costs. Afrezza is the savior, and it costs much less than Sovaldi which has already been approved by some insurance.
we make money and then spend money like rockstars, better for the economy. Spread the wealth around, even to strippers. I can donate 1,000 of my shares for this party.
great! Bill is responsible for girls. We will need at least 1:1 ratio, depending on the number of guys showing up.
when that day comes, I will try to email Alfred Mann and have him as the guest of honor.
I will coordinate it-- girls, booze, and whatever you can think of. Anyone in?
either you believe Afrezza to be a blockbuster or you don't. Can't compare this to Exubra, the size of a bong that patients couldn't even fit into their purse. It's a simple logic, would you rather stick yourself with a small needle or assemble a bong before each use? Needle any time. Would you rather take out your whistle and inhale or stick a needle? Whistle any time.
And if I was a diabetic concerned about getting leg amputation, rotten wounds, kidney failure, blindness, and heart failure down the road I would consider Afrezza that allows me to control my blood sugar within less that 12-15 minutes, while injection could require anywhere from 45-60 minutes to take effect.
It's a blockbuster all the way to the bank.
Take your pick folks, you want to increase your portfolio by 10 folds or follow your idiot shorts (Adam Fartstain and Toubillin/Karp) and make your $2 drop of a killing?!!!! That's right, this stock was trading $4-6 facing FDA rejection prior Adcom, and $10-11 prior to FDA final approval. It would be extremely unlikely for mnkd to ever trade below $6 (facing FDA rejection). Thus for Karp to state that mnkd may fall to $1/sh, after FDA approval, before the drug hit the market, potential partner, buyout, is as logical and sane as a #$%$ giving his speculation. If he was sane while making such statement, what was he smoking?
May I remind Karp and Fartstain that the market for insulin is projected to be $30-60 billion/yr in 2016. Afrezza may get a small chunk of that, especially short acting insulin. A new niche in the diabetic market is what makes Afrezza a blockbuster because it works like your native pancreas, peak action within 12-15 minutes after inhalation. Thus, EVERY diabetic who ever worry about losing their eyesights, kidneys, and heart failure will want to get on Afrezza to better control their glucose levels.
These short #$%$s do not fully understand how diabetes lose their eyesight, kidneys, and heart function after 10- 20 years of poorly controlled blood sugar. It is the uncontrolled glucose surges after a meal, a splurge, or soft drink over the years that kills. NO INSULIN IN THE MARKET CAN DO WHAT AFREZZA CAN-- the quick short acting that behaves like your own pancreas. The ease of use without the need for needles will make this a user friendly blockbuster. Cover up you sons of biatches!!! it's 80 mil shares shorted now! Massive squeeze is coming in less than 2 weeks.
short more or you can come to my house and I will show you a real upstick LOL
Afrezza creates a new niche to diabetic treatment for tighter glucose control which will show to reduce heart failure, kidney failure, and loss of eyesight. AND afrezza will compete with all short acting insulins.
Dumb shorts don't know anything about medince, stay out of the kitchen if you don't know the ingredients!
very surprised to see that some of my messages got deleted but others are left on. I didn't know they have workers reading the content and decide which to delete. Very fishy and manipulative here. I added more shares today.
Afreeza new diabetic niche to tighter glucose control that lowers kidney failure, heart failure, and loss of eyesight. AND replaces all short acting insulins.
Shorts put your head in the guillotine, and you are allowed to say your last words (articles).
the dip happened since day 2 post FDA, this is a massacre due to short scare tactic; they will pay soon.